Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy.
2/5 보강
TL;DR
Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3'-ALK fusions, however, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
89 patients who received first-line ALK-TKIs were assessed to determine therapeutic outcomes based on ALK rearrangement subtypes.
I · Intervention 중재 / 시술
first-line ALK-TKIs were assessed to determine therapeutic outcomes based on ALK rearrangement subtypes
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3'-ALK fusions. However, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
Lymphoma Diagnosis and Treatment
Chronic Lymphocytic Leukemia Research
Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3'-ALK fusions, however, their poorer prognosis do
- p-value P = 0.048
- HR 1.805
APA
Dujiang Liu, Kaibo Ding, et al. (2026). Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 28(5), 1882-1892. https://doi.org/10.1007/s12094-025-04085-8
MLA
Dujiang Liu, et al.. "Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy.." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 28, no. 5, 2026, pp. 1882-1892.
PMID
41247418
Abstract 한글 요약
[BACKGROUND] Although tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes in patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), the efficacy of current TKIs for emerging ALK rearrangement subtypes warrants further investigation, particularly with the advancements in genomic sequencing technologies.
[METHODS] We retrospectively analyzed 118 NSCLC patients with ALK rearrangements identified by next-generation sequencing (NGS) from January 2015 to April 2024. Among these, 89 patients who received first-line ALK-TKIs were assessed to determine therapeutic outcomes based on ALK rearrangement subtypes.
[RESULTS] Among 118 NSCLC patients, 36 (30.5%) harbored nonreciprocal/reciprocal translocations, 73 (61.9%) carried solitary EML4-ALK fusion, and 9 (7.6%) had solitary non-EML4-ALK fusions. Of the 89 patients treated with first-line TKIs, 60 (67.4%) had solitary 3'-ALK fusions, whereas 29 (32.6%) exhibited nonreciprocal/reciprocal ALK translocations. Compared with patients harboring solitary 3'-ALK fusions, those with nonreciprocal/reciprocal translocations experienced significantly shorter median progression-free survival (mPFS) (15.6 vs. 31.1 months; HR = 1.805; P = 0.048), although no significant difference in median overall survival (mOS) was observed (66.6 vs. 75.7 months; HR = 1.162; P = 0.714). Additionally, TP53 mutations were the most common co-occurring alterations in both groups, with no significant difference in frequency (P = 0.650).
[CONCLUSIONS] Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3'-ALK fusions. However, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.
[METHODS] We retrospectively analyzed 118 NSCLC patients with ALK rearrangements identified by next-generation sequencing (NGS) from January 2015 to April 2024. Among these, 89 patients who received first-line ALK-TKIs were assessed to determine therapeutic outcomes based on ALK rearrangement subtypes.
[RESULTS] Among 118 NSCLC patients, 36 (30.5%) harbored nonreciprocal/reciprocal translocations, 73 (61.9%) carried solitary EML4-ALK fusion, and 9 (7.6%) had solitary non-EML4-ALK fusions. Of the 89 patients treated with first-line TKIs, 60 (67.4%) had solitary 3'-ALK fusions, whereas 29 (32.6%) exhibited nonreciprocal/reciprocal ALK translocations. Compared with patients harboring solitary 3'-ALK fusions, those with nonreciprocal/reciprocal translocations experienced significantly shorter median progression-free survival (mPFS) (15.6 vs. 31.1 months; HR = 1.805; P = 0.048), although no significant difference in median overall survival (mOS) was observed (66.6 vs. 75.7 months; HR = 1.162; P = 0.714). Additionally, TP53 mutations were the most common co-occurring alterations in both groups, with no significant difference in frequency (P = 0.650).
[CONCLUSIONS] Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3'-ALK fusions. However, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- Progress in the Treatment of Refractory Myasthenia Gravis.
- Succinylation: A Functional Nexus Between Metabolic Reprogramming and Epigenetic Modifications in Cancer.
- LAPTM4B Confers Resistance to EGFR-TKIs by Suppressing the Proteasomal Degradation of ATP1A1 in Non-small Cell Lung Cancer.
- Liver metastasis ablation combined with PD-1 inhibitors improves immunotherapy efficacy: A multicenter cohort study.
- Machine learning derived proliferating T cell-related signature: a novel biomarker for prognosis and treatment efficacy in clear cell renal cell carcinoma.